Skip to main content
SpringerLink
Log in

Transparency of Economic Evaluations of Health Technologies

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drummond MF. Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 1992; 1: 8–13

    Article  PubMed  CAS  Google Scholar 

  2. Antoñanzas F, Figueras M, Rovira J. Analysing the role of economic evaluation on decision-making in the health care system in Spain: a focus group approach. In: Gran von der Schulenburg JM, editor. The influence of economic evaluation studies on health care decision making. Amsterdam: IOS Press, 2000

    Google Scholar 

  3. Jacobs P, Bachynsky J, Baladi JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8: 182–9

    Article  PubMed  CAS  Google Scholar 

  4. Reinhardt UE. Making economic evaluations respectable. Soc Sci Med 1997; 45: 555–62

    Article  PubMed  CAS  Google Scholar 

  5. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5

    Article  PubMed  CAS  Google Scholar 

  6. Task force on principles for economic analysis of economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 123: 61-70

    Google Scholar 

  7. Kassirer JP, Angell M. The journal’s policy on cost-effectiveness analysis. N Engl J Med 1994; 331: 669–70

    Article  PubMed  CAS  Google Scholar 

  8. Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr Oncol Rep 2001; 3: 410–3

    Article  PubMed  CAS  Google Scholar 

  9. Sacristán JA, Bolaños E, Hernández JM, et al. Publication bias in health economics. Pharmacoeconomics 1997; 11: 289–91

    Article  PubMed  Google Scholar 

  10. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313 (7052): 275–83

    Article  PubMed  CAS  Google Scholar 

  11. Jefferson T, Smith R, Yee Y, et al. Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and the Lancet. JAMA 1998; 280: 275–7

    Article  PubMed  CAS  Google Scholar 

  12. De Angelis C, Drazen JM, Frizelle FA, et al. International Committee of Medical Journal Editors. Editorial clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351: 1250–1

    Article  PubMed  Google Scholar 

  13. Smith R. Medical j ournals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2 (5): e 13 8

    Article  Google Scholar 

  14. Martinson BC, Anderson MS, De Vries R. Scientists behaving badly. Nature 2005; 435: 737–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Economics, University of Barcelona, Barcelona, Spain

    Joan Rovira

Authors
  1. Joan Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rovira, J. Transparency of Economic Evaluations of Health Technologies. Pharmacoeconomics 26, 181–183 (2008). https://doi.org/10.2165/00019053-200826030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200826030-00002

Search

Navigation